UNSPSC 51132222: Acetaminophen/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132222 Acetaminophen/phenobarbital is a Commodity code that does not align with the recent state and local opportunities tagged under it. The three most recent solicitations — from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance — seek naloxone and drug deactivation systems, direct-to-manufacturer pharmacy benefit management, and generic multi-source pharmaceuticals with OTC products respectively. None of these procurements target acetaminophen/phenobarbital formulations as a primary or named product line. The code shows minimal relevant recent activity for the specific pharmaceutical combination it names, suggesting either inconsistent tagging by issuing bodies or a mismatch between the code's narrow scope and the broader pharmaceutical procurement activity state and local governments are conducting.

When recent activity does appear under this code, it reflects state health agencies, county health departments, and multistate cooperative purchasing vehicles procuring pharmaceutical products through competitive bidding (IFB, RFP) with response dates ranging from April through July 2026. Seminole County's IFB for naloxone and drug deactivation systems closed July 26, 2023, and the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products closed March 26, 2026, with awards effective July 1, 2026. These solicitations require vendors to meet FDA compliance, cGMP certification, supply chain security standards, and insurance minimums of $2 to $5 million in coverage. Geographic activity centers on Florida, Texas, Minnesota, and Oregon through cooperative purchasing arrangements. If pursuing this code, verify actual product specifications in each RFP or RFQ carefully, as the code assignment may not reflect what is actually being purchased.